Antidepressant tolerability in anxious and depressed youth at high risk for bipolar disorder: A prospective naturalistic treatment study

Bipolar Disorders

Volumn 16, Issue 5, 2014, Pages 523-530

  Strawn, Jeffrey R ^a   Adler, Caleb M ^a   Mcnamara, Robert K ^a   Welge, Jeffrey A ^a   Bitter, Samantha M ^a   Mills, Neil P ^a   Barzman, Drew H ^b   Cerullo, Michael A ^a   Chang, Kiki D ^c   Strakowski, Stephen M ^a   Delbello, Melissa P ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety disorders; Bipolar disorder; Major depressive disorder; Mania; SSRI

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LAMOTRIGINE; NEUROLEPTIC AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ADOLESCENT; ADULT; AGGRESSION; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BIPOLAR I DISORDER; CHILD; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC VALUE; DISRUPTIVE BEHAVIOR; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV-TR; FEMALE; FOLLOW UP; HAMILTON SCALE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PSYCHOSIS; RISK FACTOR; SEMI STRUCTURED INTERVIEW; SUICIDAL IDEATION; TREATMENT DURATION; TREATMENT OUTCOME; YOUNG MANIA RATING SCALE; ANXIETY; DISEASE COURSE; PROBABILITY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RISK; YOUNG ADULT;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ANXIETY; BIPOLAR DISORDER; CHILD; DEPRESSION; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; PROBABILITY; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RISK; YOUNG ADULT;

EID: 84905262209     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12113     Document Type: Article

References (38)

1. McGuffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003; 60: 497-502.
2. Smoller JW, Finn CT. Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet 2003; 123C: 48-58.
3. Strober M, Carlson G. Bipolar illness in adolescents with major depression: clinical, genetic, and psychopharmacologic predictors in a three to four-year prospective follow-up investigation. Arch Gen Psychiatry 1982; 39: 549-555.
4. Chang KD, Steiner H, Ketter TA. Psychiatric phenomenology of child and adolescent bipolar offspring. J Am Acad Child Adolesc Psychiatry 2000; 39: 453-460.
5. Geller B, Zimerman B, Williams M, Bolhofner K, Craney JL. Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder. Am J Psychiatry 2001; 158: 125-127.
6. Singh MK, DelBello MP, Stanford KE et al. Psychopathology in children of bipolar parents. J Affect Disord 2007; 102: 131-136.
7. Dineen Wagner K. Bipolar disorder and comorbid anxiety disorders in children and adolescents. J Clin Psychiatry 2006; 67: 16-20.
8. Birmaher B, Brent D; AACAP Work Group on Quality Issues et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 2007; 46: 1503-1526.
9. Cheung AH, Emslie GJ, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J Child Psychol Psychiatry 2005; 46: 735-754.
10. Connolly SD, Bernstein GA; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry 2007; 46: 267-283.
11. Strawn JR, Wehry AM, DelBello MP, Rynn MA, Strakowski SM. Establishing the neurobiologic basis of treatment in children and adolescents with generalized anxiety disorder. Depress Anxiety 2012; 29: 328-339.
12. Strawn JR, Sakolsky DJ, Rynn MA. Psychopharmacologic treatment of anxiety disorders in children and adolescents. Child Adolesc Psychiatric Clin 2012; 21: 527-539.
13. Cicero D, El-Mallakh RS, Holman J, Robertson J. Antidepressant exposure in bipolar children. Psychiatry 2003; 66: 317-322.
14. Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 2004; 158: 773-780.
15. Reichart CG, Nolen WA. Earlier onset of bipolar disorder in children by antidepressants or stimulants? An hypothesis J Affect Disord 2004; 78: 81-84.
16. Baumer F, Howe M, Gallelli K, Simenova DI, Hallmayer J, Chang KD. A pilot study of antidepressant-induced mania in pediatric bipolar disorder: characteristics, risk factors, and the serotonin transporter gene. Biol Psychiatry 2006; 60: 1005-1012.
17. Faedda GL, Baldessarini RJ, Glovinsky IP, Austin NB. Treatment-emergent mania in pediatric bipolar disorder: a retrospective case review. J Affect Disord 1998; 82: 149-158.
18. Bechdolf A, Nelson B, Cotton SM et al. A preliminary evaluation of the validity of at-risk criteria for bipolar disorders in help-seeking adolescents and young adults. J Affect Disord 2010; 127: 316-320.
19. Findling RL, Lingler J, Rowles BM, McNamara NK, Calabrese JR. A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity. J Child Adolesc Psychopharmacol 2008; 18: 615-621.
20. Findling RL, Reed MD, Myers C et al. Paroxetine pharmacokinetics in depressed children and adolescents. J Am Acad Child Adolesc Psychiatry 1999; 38: 952-959.
21. Goldsmith M, Singh M, Chang K. Antidepressants and psychostimulants in pediatric populations. Is there an association with mania? Paediatr Drugs 2011; 13: 225-239.
22. Leon AC, Solomon DA, Mueller TI et al. A brief assessment of psychosocial functioning of subjects with bipolar disorder: the Longitudinal Interval Follow-Up Examination-RIFT. Longitudinal Interval Follow-Up Evaluation-Range Impaired Functioning Tool. J Nerv Ment Dis 2000; 188: 805-812.
23. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
24. Maalouf FT, Porta G, Vitiello B et al. Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study. J Affect Disord 2012; 138: 86-95.
25. Miklowitz DJ, Chang KD, Taylor DO et al. Early psychosocial intervention for youth at risk for bipolar I or II disorder: a one-year treatment development trial. Bipolar Disord 2011; 13: 67-75.
26. Geller B, Cooper TB, Zimerman B et al. Lithium for prepubertal depressed children with family history predictors of future bipolarity: a double-blind, placebo-controlled study. J Affect Disord 1998; 51: 165-175.
27. Chang KD, Dienes K, Blasey C, Adleman N, Ketter T, Steiner H. Divalproex monotherapy in the treatment of bipolar offspring with mood and behavioral disorders and at least mild affective symptoms. J Clin Psychiatry 2003; 64: 936-942.
28. Findling RL, Frazier TW, Youngstrom EA et al. Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder. J Clin Psychiatry 2007; 68: 781-788.
29. DelBello MP, Adler CM, Whitsel RM, Stanford KE, Strakowski SM. A 12-week single blind trial of quetiapine for the treatment of mood symptoms in adolescents at high risk for developing bipolar I disorder. J Clin Psychiatry 2007; 68: 789-795.
30. Amminger GP, Schäfer MR, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146-154.
31. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 2006; 163: 1098-1100.
32. Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, Garg ML, Hazell PL. Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr 2009; 63: 1037-1040.
33. Wozniak J, Biederman J, Mick E et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol 2007; 17: 440-447.
34. Nadkarni RB, Fristad MA. Clinical course of children with a depressive spectrum disorder and transient manic symptoms. Bipolar Disord 2010; 12: 494-503.
35. Marcus SM, Gorman J, Shear MK et al. A comparison of medication side effect reports by panic disorder patients with and without concomitant cognitive behavior therapy. Am J Psychiatry 2007; 164: 273-275.
36. Walkup JT, Albano AM, Piacentini J et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med 2008; 359: 2753-2766.
37. Brent D, Emslie G, Clarke G et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA 2008; 299: 901-913.
38. McNamara RK, Nandagopal JJ, Strakowski SM, DelBello MP. Preventative strategies for early-onset bipolar disorder: towards a clinical staging model. CNS Drugs 2010; 24: 983-996.